2020
A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer
Barroso-Sousa R, Krop IE, Trippa L, Tan-Wasielewski Z, Li T, Osmani W, Andrews C, Dillon D, Richardson ET, Pastorello RG, Winer EP, Mittendorf EA, Bellon JR, Schoenfeld JD, Tolaney SM. A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer. Clinical Breast Cancer 2020, 20: 238-245. PMID: 32113750, DOI: 10.1016/j.clbc.2020.01.012.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalBiomarkers, TumorBreastBreast NeoplasmsCarcinoma, Ductal, BreastChemoradiotherapyDrug Administration ScheduleFemaleHumansInfusions, IntravenousMiddle AgedPalliative CareProgrammed Cell Death 1 ReceptorProgression-Free SurvivalReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneResponse Evaluation Criteria in Solid TumorsConceptsMetastatic breast cancerHormone receptor-positive metastatic breast cancerProgression-free survivalRadiation therapyObjective responseOverall survivalBreast cancerResponse rateMedian progression-free survivalCause adverse eventsGrade 3 eventsMedian prior linesMedian overall survivalObjective response ratePalliative radiation therapyPhase II studyTumor-infiltrating lymphocytesLymph node lesionsOverall response rateEpidermal growth factor receptorEligible patientsExploratory endpointsGrowth factor receptorPalliative radiotherapyPrimary endpoint
2017
Factors Associated with Early Mortality Among Patients with De Novo Metastatic Breast Cancer: A Population‐Based Study
Vaz‐Luis I, Lin NU, Keating NL, Barry WT, Winer EP, Freedman RA. Factors Associated with Early Mortality Among Patients with De Novo Metastatic Breast Cancer: A Population‐Based Study. The Oncologist 2017, 22: 386-393. PMID: 28242790, PMCID: PMC5388378, DOI: 10.1634/theoncologist.2016-0369.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedBreast NeoplasmsFemaleHumansMiddle AgedNeoplasm MetastasisPalliative CareConceptsMetastatic breast cancerMonths of diagnosisQuarter of patientsEarly deathBreast cancerPoor outcomeUninsured statusHigh riskDe novo metastatic breast cancerEarly palliative care referralNovo metastatic breast cancerHuman epidermal growth factor receptor 2Older ageEpidermal growth factor receptor 2Palliative care referralHalf of patientsProportion of patientsEnd Results (SEER) dataGrowth factor receptor 2Identification of patientsClinical trial participationFactor receptor 2Additional supportive servicesProportion of womenEquitable patient access
2016
3rd ESO–ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3)
Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios C, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso M, Carey L, Corneliussen-James D, Curigliano G, Dieras V, Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Pernault-Llorca F, Piccart M, Pierga J, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. 3rd ESO–ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). The Breast 2016, 31: 244-259. PMID: 27927580, DOI: 10.1016/j.breast.2016.10.001.Peer-Reviewed Original Research
2014
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios C, Bergh J, Biganzoli L, Blackwell K, Cardoso M, Cufer T, Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano S, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin U, Mayer M, Merjaver S, Nordström E, Pagani O, Partridge A, Penault-Llorca F, Piccart M, Rugo H, Sledge G, Thomssen C, Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). The Breast 2014, 23: 489-502. PMID: 25244983, DOI: 10.1016/j.breast.2014.08.009.Peer-Reviewed Original Research
1996
Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancer.
Chu L, Sutton LM, Peterson BL, Havlin KA, Winer EP. Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancer. The Journal Of Infusional Chemotherapy 1996, 6: 211-6. PMID: 9229318.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerSymptom Distress ScaleFunctional Living Index-CancerFirst-line settingFirst-line therapyBreast cancerContinuous infusionDisease progressionPrevious phase II studyRefractory metastatic breast cancerAdequate bone marrowContinuous infusion fluorouracilGrade 3 mucositisECOG performance statusMedian overall survivalObjective response ratePhase II studyContinuous intravenous infusionQuality of lifeEvaluable diseaseFLIC scoresInfusion fluorouracilMeasurable diseasePrior chemotherapyIndex cancer